Maria Luisa De Rimini on LinkedIn: Considerations on the preliminary results of the NETTER-2 trial: is the… (2024)

I am delighted to share with you our latest published work on the iRhom2-ADAM17 complex in Tylosis Oesophageal Carcinoma (TOC):“Pathological mutations reveal the key role of the cytosolic iRhom2 N-terminus for phosphorylation-independent 14-3-3 interaction and ADAM17 binding, stability, and activity”https://lnkd.in/ePpWAtnE#ADAM17 #Proteases #cancer

32

📃Scientific paper: Biological distinction between grades 2 and 3 with respect to intravesical recurrence in T1 high-grade bladder tumors: a retrospective studyAbstract:Background The pathological grading system for non-muscle-invasive bladder cancer is based on the WHO 2004/2016 classification system (low-grade: LG/high-grade: HG) and the WHO 1973 classification system (Grade 1: G1/Grade 2: G2/Grade 3: G3).Recently, the usefulness of combining both systems and classifying the tumors as LG/G1, LG/G2, HG/G2, and HG/G3 has been demonstrated.In this study, we compared the prognosis of intravesical recurrence in relation to different treatment intensities between HG/G2 and HG/G3 bladder cancers.Methods We retrospectively evaluated the clinical and therapeutic outcomes of 145 patients diagnosed with T1 HG bladder cancer between 2000 and 2020.We classified 145 patients into three groups: (1) patients with T1 HG/G2 and HG/G3 who received intravesical instillation therapy (n = 76), (2) patients with T1 HG/G2 who did not receive intravesical instillation therapy (n = 32), and (3) patients with T1 HG/G3 who did not receive intravesical instillation therapy (n = 37).Results The median intravesical recurrence-free survival for all patients was 34.2months.The number of tumors, the presence of intravesical instillation therapy, and tumor grade were significant prognostic factors for intravesical recurrence in all cases.Groups 2 and 3 showed significantly worse prognosis than group 1 in the multivariate analysis.Conclusions Regarding intravesical recurrence, intravesical instillation therapy is necessary for both T1 HG/G3 and T1 HG/G2 bl... Discover the rest of the scientific article on es/iode ➡️https://etcse.fr/4Ld3

CheckMate 714 is a randomized phase II trial testing nivolumab with or without ipilimumab in patients with platinum-refractory or platinum-eligible recurrent or metastatic squamous cell carcinoma of the head/neck (SCCHN), finding no improvement in efficacy with the combination. https://ja.ma/3Pimwo3

31

Salivary adenoid cystic carcinoma (SACC) is an aggressive tumor that exhibits a neurotropic growth pattern by invading nerve fibers and demonstrates a high tendency for both local spread and early distant metastases. The limited availability of successful chemotherapeutic regimens represents a major obstacle in the efficient treatment of SACC patients.Through epithelial-mesenchymal transition (EMT), cancer cells gain increased motility and invasiveness, facilitating their ability to infiltrate the basem*nt membrane and disseminate to distant sites in the body. In this review, we provide a comprehensive overview of the latest research on the role of EMT in SACC, including the molecular pathways and biomarkers involved in EMT regulation. By highlighting the most recent findings, our manuscript offers insights into potential new therapeutic strategies that could improve the management of SACC patients, especially those with recurrent or metastatic disease.A heartfelt thank you to Fabian Stögbauer and Barbara Wollenberg for their valuable support and outstanding teamwork.Link to article: https://lnkd.in/eH3xqtUR#teamwork #epithelialmesenchymaltransition #mesenchymalepithelialtransition #epithelialmesenchymalplasticity #salivaryadenoidcysticcarcinoma #metastasis #biomarkers

44

5 Comments

A proposal to revamp tumor naming system -- the new system would be based on molecular characteristics rather than the organ-based classification currently in use. This shift would positively impact how clinicians & researchers are trained, how patients are identified & recruited for clinical trials, and ultimately how patients are treated for their cancers. #precisiononcology #genomicmedicine https://lnkd.in/g4YwmXum?

47

2 Comments

🔬 Over C™: Pioneering Methylation-based Multi-Cancer Early Detection (MCED) Technology with Global RecognitionOverC™ MCED is intended for early detection of multiple cancer types (esophageal, liver, lung, ovarian, and pancreatic cancers) in adults of either sex, aged 50-75 years old, at average risk for cancer.🌍 Key Milestones:·Received "Breakthrough Device Designation" by both the FDA and NMPA.·Clinical validation published in the Annals of Oncology.·Based on the ELSA-seq technology platform (MCDBT-1 model), achieving 98.9% specificity and 69.1% sensitivity across six major cancers, and will be further validated in prospective interventional studies among asymptomatic population.·Outstanding tissue origin tracing capabilities, with accuracy rates of 83.2% for primary and 91.7% for both primary and secondary organs.📈 Clinical Impact:In real-world simulations, ELSA-seq shifted 38.7%-46.4% of late-stage cancers to earlier stages, increasing 5-year survival rates by 33.1%-40.4%.🌐 Learn more about OverC™: https://lnkd.in/gjGX3ZSa#OverC #CancerScreening #EarlyDetection #BurningRock #Liquid Biopsy

6

😆 Exciting news! --- 📚 The latest article from ETAT Journal is now available online! 📄 Titled "DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine". This insightful piece by Jingxin Ye, Jianfeng Zhang* and Weifeng Ding* 📩 This review compiles a comprehensive body of evidence underscoring the significant involvement of DNA methylation modifications in the pathogenesis of CRC. Moreover, this review explores the potential utility of DNA methylation in cancer diagnosis, prognostics, assessment of disease activity, and prediction of drug responses. Recognizing the impact of DNA methylation will enhance the ability to identify distinct CRC subtypes, paving the way for personalized treatment strategies and advancing precision medicine in the management of CRC. 📍 Access the full text at:https://lnkd.in/g7RmMvEb 🔓 The PDF version is also available for download:https://lnkd.in/gRYJkr4v 💯 Don't miss out on this exciting opportunity to expand your knowledge and stay up-to-date with the latest developments. ❗ Happy reading! #EpigeneticModification, #DNA #methylation, #ColorectalCancer, #Diagnosis, #MetabolismReprogramming

6

Fibroblast heterogeneity in the tumor microenvironment is so important in tumor progression. Check out this interesting paper that highlights the biological markers of these populations and their clinical relevance.

1

Identification of stromal cell-derived factor 4 as a liquid biopsy-based diagnostic marker in solid cancersNaturehttps://lnkd.in/g4Ua_McT

Gastrointestinal pan-cancer landscape of tumor matrix heterogeneity identifies biologically distinct matrix stiffness subtypes predicting prognosis and chemotherapy efficacy.Read the article here: https://lnkd.in/d67PyGdn